drugset / Trial / NCT03398759

Butorphanol Mitigate Emergence Agitation in Patients Undergoing Functional Endoscopic Sinus Surgery

NCT03398759

Unknown 700 enrolled RenJi Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Emergence agitation is one of the common postoperative complications after functional endoscopic sinus surgery(FESS). The objective of present study is to explore the effectiveness of butorphanol in the alleviation of emergence agitation in patients undergoing Functional Endoscopic Sinus Surgery.

Timeline

Start
2018-02-01
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Butorphanol Other / unclassified 20 ug/kg Intravenous

Indications

No indication recorded.